Sharjeel Syed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sharjeel Syed has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Radhika Peddinti
Section of Hematology/Oncology and Stem Cell Transplantation Department of Pediatrics University of Chicago Chicago Illinois USA
3 shared publications- Wendy S. Darlington
Section of Hematology/Oncology and Stem Cell Transplantation Department of Pediatrics University of Chicago Chicago Illinois USA
3 shared publications Gabrielle Lapping‐Carr
Section of Hematology/Oncology and Stem Cell Transplantation Department of Pediatrics University of Chicago Chicago Illinois USA
2 shared publicationsKristen Wroblewski
Department of Public Health Sciences University of Chicago Chicago Illinois USA
2 shared publicationsAndrew Palmer
Pritzker School of Medicine Chicago Illinois USA
1 shared publication- Austin Wesevich
University of Chicago
1 shared publication
Latest Publications
- Open Access
- 3 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32100
Association of Food Insecurity With Disease‐Related Complications and Healthcare Utilization for Patients With Sickle Cell Disease
Background: Food insecurity is one of several household material hardships (HMH) recognized for their impact on disease severity and healthcare utilization in patients with chronic disease. Sickle cell disease (SCD) is a chronic disease, disproportionately affecting patients of lower socioeconomic status, that results in high rates of disease‐related complications and high healthcare utilization. This study examines the relationship between food insecurity and SCD‐related complications and healthcare utilization. Methods: Patients (ages 2–24 years) and/or their parents were surveyed to assess food insecurity status during routine SCD clinic visits from July 2015 to July 2019. Food insecurity status was assessed using the United States Department of Agriculture (USDA) Food Security Short Form (six‐item), with a lookback period of 12 months. Sociodemographic characteristics, disease‐related complications, and healthcare utilization were abstracted from electronic health records. Results: Overall, 22% ( n = 25) of participant households were food insecure. Food insecurity was associated with significantly higher annual rates of acute chest syndrome (aOR = 3.12, 95% CI: 1.27–7.67), prevalence of cholecystectomy (aOR = 6.29, 95% CI: 1.66–23.80), and a higher number of hospitalizations (aOR = 2.40, 95% CI: 1.04–5.52). Conclusions: The rates of food insecurity among sampled households of pediatric and young adult patients with SCD were much higher than national (13.4%) and local county rates (13%). Food insecurity was independently associated with more disease‐related complications and higher healthcare utilization even after adjusting for age, sex, and sickle cell type. These results suggest food insecurity may be a modifiable contributor impacting morbidity in patients with SCD and should prompt further study into these relationships.
- 3 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32100
Open AccessAssociation of Food Insecurity With Disease‐Related Complications and Healthcare Utilization for Patients With Sickle Cell Disease
Background: Food insecurity is one of several household material hardships (HMH) recognized for their impact on disease severity and healthcare utilization in patients with chronic disease. Sickle cell disease (SCD) is a chronic disease, disproportionately affecting patients of lower socioeconomic status, that results in high rates of disease‐related complications and high healthcare utilization. This study examines the relationship between food insecurity and SCD‐related complications and healthcare utilization. Methods: Patients (ages 2–24 years) and/or their parents were surveyed to assess food insecurity status during routine SCD clinic visits from July 2015 to July 2019. Food insecurity status was assessed using the United States Department of Agriculture (USDA) Food Security Short Form (six‐item), with a lookback period of 12 months. Sociodemographic characteristics, disease‐related complications, and healthcare utilization were abstracted from electronic health records. Results: Overall, 22% ( n = 25) of participant households were food insecure. Food insecurity was associated with significantly higher annual rates of acute chest syndrome (aOR = 3.12, 95% CI: 1.27–7.67), prevalence of cholecystectomy (aOR = 6.29, 95% CI: 1.66–23.80), and a higher number of hospitalizations (aOR = 2.40, 95% CI: 1.04–5.52). Conclusions: The rates of food insecurity among sampled households of pediatric and young adult patients with SCD were much higher than national (13.4%) and local county rates (13%). Food insecurity was independently associated with more disease‐related complications and higher healthcare utilization even after adjusting for age, sex, and sickle cell type. These results suggest food insecurity may be a modifiable contributor impacting morbidity in patients with SCD and should prompt further study into these relationships.
- Open Access
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study
Background: The effects of steroid-sparing immunosuppressive agents (SSIAs), used for the treatment of immune-related adverse events (irAEs), on immune checkpoint inhibitor (ICI) antitumor activity is not well known. We compared tumor outcomes of patients who received corticosteroid monotherapy (CS) versus a corticosteroid plus SSIA (CS-SSIA) for irAE treatment, using statistical methods to address immortal time bias. Methods: We conducted a retrospective case-control study on patients ≥ 18 years with melanoma or non-small-cell lung cancer (NSCLC) treated with ≥1 ICI at a quaternary care center between 1 January 2016 and 11 January 2021. Patients were divided into two cohorts: CS or CS-SSIA. We used propensity score nearest-neighbor matching to match on tumor type, stage, and prior lines of therapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included the time from the start of the irAE treatment to the irAE resolution. Hazard ratios (HRs) for PFS and OS were calculated using the Cox proportional hazard regression method with both (1) the time to the steroid and SSIA as time-varying covariates and (2) a binary exposure classification not accounting for the time to the treatment. Results: A total of 167 patients were included after matching (132 in the CS cohort and 35 in the CS-SSIA cohort). Sixty-six percent of all the patients had melanoma. The most common irAEs requiring treatment were gastroenterocolitis and hepatitis. In an adjusted analysis not accounting for immortal time bias, there were no significant differences in PFS (HR 0.75, 95% CI [0.46–1.23]) or OS (HR 0.82, 95% CI [0.46–1.47]). In analyses using a time-varying treatment indicator, there was a trend toward improved PFS in patients treated with SSIAs (HR 0.54, CI 0.26–1.10). There was no difference in OS (HR 1.11, CI 0.55–2.23). Patients with melanoma who specifically received infliximab had improved PFS compared to patients with CS only, after adjusting for immortal time bias (HR 0.32, CI 0.24–0.43). Conclusions: The use of SSIAs with CS did not have worse outcomes than CS monotherapy. In melanoma, our findings showed improved PFS for the use of infliximab versus steroid monotherapy for irAEs. Large, prospective, randomized controlled trials are needed to confirm these findings and guide the optimal treatment of irAEs.
Open AccessStudying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study
Background: The effects of steroid-sparing immunosuppressive agents (SSIAs), used for the treatment of immune-related adverse events (irAEs), on immune checkpoint inhibitor (ICI) antitumor activity is not well known. We compared tumor outcomes of patients who received corticosteroid monotherapy (CS) versus a corticosteroid plus SSIA (CS-SSIA) for irAE treatment, using statistical methods to address immortal time bias. Methods: We conducted a retrospective case-control study on patients ≥ 18 years with melanoma or non-small-cell lung cancer (NSCLC) treated with ≥1 ICI at a quaternary care center between 1 January 2016 and 11 January 2021. Patients were divided into two cohorts: CS or CS-SSIA. We used propensity score nearest-neighbor matching to match on tumor type, stage, and prior lines of therapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included the time from the start of the irAE treatment to the irAE resolution. Hazard ratios (HRs) for PFS and OS were calculated using the Cox proportional hazard regression method with both (1) the time to the steroid and SSIA as time-varying covariates and (2) a binary exposure classification not accounting for the time to the treatment. Results: A total of 167 patients were included after matching (132 in the CS cohort and 35 in the CS-SSIA cohort). Sixty-six percent of all the patients had melanoma. The most common irAEs requiring treatment were gastroenterocolitis and hepatitis. In an adjusted analysis not accounting for immortal time bias, there were no significant differences in PFS (HR 0.75, 95% CI [0.46–1.23]) or OS (HR 0.82, 95% CI [0.46–1.47]). In analyses using a time-varying treatment indicator, there was a trend toward improved PFS in patients treated with SSIAs (HR 0.54, CI 0.26–1.10). There was no difference in OS (HR 1.11, CI 0.55–2.23). Patients with melanoma who specifically received infliximab had improved PFS compared to patients with CS only, after adjusting for immortal time bias (HR 0.32, CI 0.24–0.43). Conclusions: The use of SSIAs with CS did not have worse outcomes than CS monotherapy. In melanoma, our findings showed improved PFS for the use of infliximab versus steroid monotherapy for irAEs. Large, prospective, randomized controlled trials are needed to confirm these findings and guide the optimal treatment of irAEs.
- Open Access
- 30 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31045
Food insecurity and quality of life in patients with sickle cell disease
Little is known about the relationship between quality of life (QOL) and food insecurity (FI) among patients with sickle cell disease (SCD). We hypothesized FI is associated with lower QOL in children and young adults with SCD. Overall ( N = 99), 22% screened positive for FI. Supplemental Nutrition Assistance Program (SNAP) enrollment was 50 and 71% among people from food secure and FI households, respectively. A higher FI score was correlated with lower overall QOL ( r = −0.22, p = .03), specifically lower QOL in worry and communication domains. Interventions for FI beyond SNAP may be important for QOL among people living with SCD.
- 30 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31045
Open AccessFood insecurity and quality of life in patients with sickle cell disease
Little is known about the relationship between quality of life (QOL) and food insecurity (FI) among patients with sickle cell disease (SCD). We hypothesized FI is associated with lower QOL in children and young adults with SCD. Overall ( N = 99), 22% screened positive for FI. Supplemental Nutrition Assistance Program (SNAP) enrollment was 50 and 71% among people from food secure and FI households, respectively. A higher FI score was correlated with lower overall QOL ( r = −0.22, p = .03), specifically lower QOL in worry and communication domains. Interventions for FI beyond SNAP may be important for QOL among people living with SCD.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 8218-8219
Area of Residence As a Screening Tool for Sickle Cell Disease Outcomes in Chicago Pediatric Patients
Background: Sickle cell disease (SCD) is a chronic condition that, in the United States, largely affects a socioeconomically vulnerable group of patients. We ha
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 8218-8219
Open AccessArea of Residence As a Screening Tool for Sickle Cell Disease Outcomes in Chicago Pediatric Patients
Background: Sickle cell disease (SCD) is a chronic condition that, in the United States, largely affects a socioeconomically vulnerable group of patients. We ha